CompletedNCT00057707
Modafinil and cognition in schizophrenia: a brain-imaging study
About this title
Read the official source — NCT00057707Medication studyAges 18–50United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 50 years.
- Listed locations
- BethesdaSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateMarch 26, 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 176
- Sponsor
- National Institute of Mental Health (NIMH)
- Sponsor type
- Government agency
- Study type
- Drug
- Intervention type
- Drug, Procedure
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT00057707
- Official title
Show the full official title
Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Modafinil on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Bethesda
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is National Institute of Mental Health (NIMH), a government agency.
Did this study involve medication?
Yes. The study involved medication, including Modafinil.
Who was this study for?
Listed age limits: 18 years to 50 years.
